New York, October 15, 2026 /PRNewswire/ — Global leader in healthcare investing, OrbiMed, today announced that it has raised $3 billion in committed capital for two new private equity funds: OrbiMed Private Investments X and OrbiMed Asia Partners VI.
OrbiMed stated that OrbiMed Private Investments X has raised over $1.9 billion to invest in venture capital opportunities in the life sciences sector in the United States and Europe. OrbiMed Asia Partners VI has raised over $1 billion to invest in venture capital and growth-stage opportunities in Asia’s healthcare sector. Both funds aim to build leading healthcare companies, with a focus on biopharmaceuticals, medical devices, diagnostics, and technology-driven healthcare services.
“There has never been a better time to invest in life sciences innovation,” said Carl Gordon, Managing Partner at OrbiMed. “The growing adoption of artificial intelligence, the proliferation of novel therapeutic modalities, and China’s rise as a global biotech powerhouse are exponentially expanding opportunities to develop transformative therapies. We look forward to helping entrepreneurs turn these advancements into leading companies in the healthcare industry.”
OrbiMed is led by 20 partners and has a team of over 150 professionals with complementary expertise in corporate incubation, strategy, operations, and finance. The company operates across 12 locations worldwide, covering major healthcare markets.
Investors in these new funds include a broad range of institutional types, such as healthcare institutions, university endowments, foundations, pension funds, sovereign wealth funds, and family offices.
“We thank our many long-term investors for their continued support,” said Carter Neild, Managing Partner at OrbiMed. “Over the coming years, we will work tirelessly to meet their high expectations.”
About OrbiMed
OrbiMed is a leading healthcare investment firm managing over $21 billion in assets. OrbiMed invests across the global healthcare industry, from startups to large multinational corporations, using investment vehicles such as private equity funds, public equity funds, and royalty/credit funds. OrbiMed aims to be the preferred capital partner by providing tailored financing solutions and leveraging its strong global team to help build world-class healthcare companies.
The OrbiMed team consists of more than 150 professionals located in New York, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other major global markets. For more information, visit www.orbimed.com.